TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations.
- DOI
- 10.3389/fonc.2025.1721624
- Published
- 2025
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2025.1721624,
title = {TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations.},
author = {Newsom-Davis T and Melosky B and Heist RS and Lu S and Pasello G and Chen X and Stachowiak M and Lyfar P and Forcina A and Ramalingam SS},
year = {2025},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2025.1721624},
url = {https://doi.org/10.3389/fonc.2025.1721624}
}RIS
TY - JOUR TI - TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. AU - Newsom-Davis T AU - Melosky B AU - Heist RS AU - Lu S AU - Pasello G AU - Chen X AU - Stachowiak M AU - Lyfar P AU - Forcina A AU - Ramalingam SS PY - 2025 JO - Frontiers in oncology DO - 10.3389/fonc.2025.1721624 UR - https://doi.org/10.3389/fonc.2025.1721624 ER -
APA
T, N., B, M., RS, H., S, L., G, P., X, C., M, S., P, L., A, F., & SS, R. (2025). TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations.. Frontiers in oncology. https://doi.org/10.3389/fonc.2025.1721624
Source records
- pubmed · retrieved 2026-09-27T09:54:10.400Z